What's actually happening during perimenopause, and why does it last so long?

How is perimenopause different from menopause?

Menopause is technically a single day, defined as 12 months after a woman's last menstrual period. Perimenopause is the long arc that surrounds it.

During the menopausal transition, roughly 50 to 75% of women have hot flashes or night sweats, which typically last more than seven years, and more than half have genitourinary symptoms such as vaginal dryness. Estrogen therapy reduces hot flash frequency by about 75% [PMID: 36749328].

Postmenopause is the entire phase of life after the menopause day. Most of what people call "menopause symptoms" are actually perimenopausal symptoms.

What's happening hormonally during perimenopause?

Progesterone falls first as ovulation becomes irregular, estrogen then swings unpredictably before it finally declines, and testosterone drifts down on its own slower schedule. The hormonal sequence has a recognizable pattern:

• Progesterone declines first, often beginning in the mid-30s as ovulation becomes less regular. Progesterone is one of the major female sex hormones, and its decline often produces the first noticeable symptoms (anxiety, sleep disruption, heavier or more painful periods, PMS that's getting worse)
• Estrogen levels start fluctuating wildly during the transition, with cycles that can swing between high and low estrogen states unpredictably. Estrogen is the dominant female sex hormone affecting tissues throughout the body
• Eventually estrogen also declines, but only late in the transition
• Testosterone follows its own gradual decline that's more linear with age, less tied to the menopause transition specifically

By postmenopause, all three are at lower levels than during reproductive years, with progesterone effectively absent.

What symptoms are actually caused by perimenopause?

Disrupted sleep, new anxiety, brain fog, weight that settles at the middle, hot flashes and night sweats, joint aches, thinning hair, palpitations, and heavier or more erratic periods are all documented perimenopausal symptoms. The symptoms span virtually every system because estrogen and progesterone act on receptors throughout the body:

• Sleep: insomnia, frequent waking (especially between 3 and 5 AM), unrefreshing sleep
• Mood: anxiety that can appear suddenly in women with no prior history, irritability, depression, mood swings tied to hormonal fluctuations
• Cognition: brain fog, word-finding difficulty, short-term memory changes, decreased mental sharpness
• Body composition: weight gain particularly around the midsection, increased difficulty losing weight, shifts in body shape independent of weight change
• Vasomotor: hot flashes, night sweats, temperature dysregulation
• Genitourinary: vaginal dryness, painful intercourse, recurrent urinary tract infections, urinary urgency
• Musculoskeletal: joint pain, muscle aches, frozen shoulder, increased injury risk
• Cardiovascular: heart palpitations, increased blood pressure, accelerated cardiovascular risk after estrogen declines
• Skin and hair: thinning hair, dry skin, accelerated facial aging, increased pigmentation changes
• Metabolic: shift toward insulin resistance, higher fasting glucose, changes in cholesterol patterns

The breadth is part of why perimenopause is so often missed; no one symptom screams "perimenopause," and many women see different specialists for different symptoms without anyone connecting them.

Why is lab testing during perimenopause so tricky?

Lab testing during perimenopause is genuinely difficult. Hormones fluctuate dramatically cycle to cycle and even within a single cycle. A blood draw on a "good day" can look entirely normal in a profoundly symptomatic woman.

The clinical history and symptom pattern often carry as much weight as labs in this transition. FSH (follicle-stimulating hormone) levels rise as ovarian function declines but can vary substantially. AMH (anti-Müllerian hormone) gives information about ovarian reserve, the body's remaining egg supply. Comprehensive cortisol metabolite panels can be useful because perimenopause and HPA axis dysfunction (the body's stress system) frequently co-occur.

Single-point hormone testing during perimenopause often misleads. Multiple time points, full panels, and clinical context together produce a more accurate picture than any single value.

What should I know about hormone therapy and the WHI study?

Hormone therapy has been substantially clarified since the early 2000s WHI study generated widespread fear. The current evidence supports hormone therapy for symptomatic women, particularly when initiated within 10 years of menopause [PMID: 33858012]. The risk-benefit profile favors treatment for most symptomatic women in this window.

The forms used now are typically transdermal estradiol, which avoids the liver-first metabolism that oral estrogen goes through, and oral micronized progesterone, which has additional sleep-supporting effects from its metabolites. Testosterone in low doses is increasingly used for libido, energy, mood, and body composition support, though it's not yet FDA-approved for women in the US.

The WHI used older formulations (conjugated equine estrogens and medroxyprogesterone) in women who were on average 63 years old at study entry, well past the early postmenopausal window. The findings of that study don't translate directly to modern bioidentical formulations initiated in symptomatic women within 10 years of menopause. Multiple medical societies now recommend hormone therapy for this population.

Why does cardiovascular risk shift around menopause?

Estrogen has cardioprotective effects in premenopausal women. After menopause, cardiovascular risk rises substantially over the following decade, eventually equaling and exceeding men's risk.

Women initiating hormone therapy within 10 years of menopause appear to maintain some of this protection [PMID: 33858012]. Women starting more than 10 years out may not, and may carry higher risk. This timing-dependent pattern is what shaped current treatment guidelines.

For women in the early postmenopausal window with symptoms or risk factors, hormone therapy is increasingly seen as a meaningful tool for cardiovascular protection rather than an avoidable risk.

How does perimenopause affect bones?

Bone density loss accelerates dramatically in the first 5 years after menopause, with up to 20% of bone mass loss possible in this window. DEXA scanning, fracture risk assessment, and either hormone therapy or other bone-protective interventions matter for long-term outcomes.

This is one of the strongest arguments for proactive evaluation in the late perimenopausal and early postmenopausal years. The window for preventing the steepest bone loss is narrow, and the trajectory determined in this window carries forward for decades.

What about the cognitive changes?

Cognitive changes in perimenopause are real and physiological, not psychological. Estrogen supports cholinergic neurons (the memory-related nerve cells), serotonergic activity (affecting mood), and cerebral blood flow. The brain is going through its own transition during the hormonal shift.

Most cognitive symptoms stabilize after the perimenopausal window, but some women experience persistent changes. Hormone therapy may have cognitive benefits when initiated early, though the evidence is still being clarified through ongoing trials.

Which hormone tests are worth doing in perimenopause, and when in the cycle?

No single blood test diagnoses perimenopause, so the hormone tests worth doing are the ones that add information: FSH and estradiol drawn in the first days of a cycle, progesterone timed about a week after ovulation, AMH read against age and cycle pattern, and the markers that explain the same symptoms from outside the ovary, a full thyroid panel, iron studies with ferritin, and fasting insulin. For a woman over 45 whose hot flashes have recently started and whose cycle has changed, the recognition rests on that history, and the NICE guideline identifies perimenopause in that group without laboratory tests [Source: NICE 2026 Menopause: identification and management NG23].

A single estradiol or FSH can look normal while the symptoms are real because the transition is characterized by wide hormonal swings, within a cycle and from one cycle to the next [PMID: 33095879]. FSH, the pituitary's signal to the ovaries, climbs in a month when the ovaries respond poorly and falls back in a month when a follicle answers; estradiol can run higher than in earlier years in one cycle and low in the next. A draw that lands on a responsive month reads as reassuring, and a draw a few weeks later can read as menopausal. Hormonal contraception adds a second problem: it suppresses the very signals the test is meant to read, which is why the same guideline advises against using FSH to identify menopause in someone using combined contraception [Source: NICE 2026 Menopause: identification and management NG23].

Timing is what turns these numbers into information. In a woman who is still cycling, FSH and estradiol are read at their baseline in the first few days of a period, the conventional day 3 draw, because an estradiol taken on a random day has no baseline to be compared against. Progesterone, the hormone the ovary makes only after ovulation, is informative about seven days after ovulation, roughly a week before the next period is expected; that is the draw often called day 21, though it falls on a different day in a longer or shorter cycle. A low value at that point means the cycle did not ovulate, which is the earliest hormonal change of the transition. Once cycles have become erratic, a physician often repeats FSH across two or three cycles or sets the hormones aside and reads the bleeding pattern, which is what the staging system used in research is built on [PMID: 22344196].

• AMH, made by the small follicles left in the ovary, estimates how close the final period is better than FSH does, though as a probability rather than a date: in a large study of women in their late 40s, a very low AMH meant roughly a coin-flip chance of the final period arriving within a year for those under 48, and about four in five for those 51 and older [PMID: 31965189]
• TSH, free T4 and thyroid antibodies, because thyroid disease produces the same fatigue, sleep disruption, cycle changes and mood shifts, and can sit alongside the transition unnoticed
• Ferritin with a complete iron panel, because heavier or more frequent periods in the transition drain iron, and low iron produces fatigue, hair shedding and palpitations that get blamed on hormones
• Fasting insulin, because midlife insulin resistance shares much of this picture, which the next section covers
• Prolactin and a pregnancy test when periods stop abruptly rather than drifting, since both can mimic the transition

What a physician reads instead of one number is the trajectory: age, the cycle pattern over the past year, which symptoms cluster together and when they started, and the markers that rule other explanations in or out. That reading decides whether a normal level is reassuring or beside the point, which is why the menstrual history carries as much weight as the panel. Bleeding that returns after twelve months without a period, bleeding between periods that persists, or bleeding heavy enough to soak through protection hour after hour needs prompt evaluation rather than a hormone panel.

When do cycle changes point to blood sugar rather than perimenopause?

Cycle changes point toward blood sugar rather than perimenopause when cycles that were never quite regular are stretching out further, when the change tracks a shift in weight rather than a stage of life, and when it arrives with weight at the waist, an energy slump after meals, darkened skin creases, skin tags or acne along the jawline; they point toward the ovarian transition when a previously regular cycle shortens and grows heavier before it starts to skip, and when night sweats, new sleep disruption and a rising FSH arrive with it. In the 40s the honest answer is often both, and the workup exists to say how much of each.

The two overlap because each one feeds the other. Falling estrogen shifts fat storage toward the abdomen, and abdominal fat itself worsens insulin resistance; in a four-year study that followed women through the transition, the women who crossed into menopause gained deep abdominal fat and burned less fat, while those who stayed premenopausal did not [PMID: 18332882]. Insulin resistance, meaning the cells respond less to insulin so the pancreas makes more of it, in turn lowers SHBG, the protein that carries sex hormones in the blood, which raises free testosterone and can disrupt ovulation, thin scalp hair and bring acne, changes that look perimenopausal and partly are. That is why weight at the middle, fatigue, disrupted sleep, brain fog, low mood and irregular cycles appear on both lists.

A workup separates them by measuring both sides in the same draw and reading them against the cycle history. On the blood-sugar side: fasting insulin and HOMA-IR, which catch insulin resistance before glucose moves, HbA1c, triglycerides against HDL, and a waist measurement. On the ovarian side: FSH and estradiol early in the cycle, AMH in context, total and free testosterone with SHBG and DHEA-S, and a cycle diary that records length, flow and skipped months. A high fasting insulin with low SHBG, elevated androgens and long cycles is the blood-sugar picture, and in a woman in her 40s it can be polycystic ovary syndrome that was never named, since the condition does not retire with age; a rising FSH with a low AMH, cycles that shortened before they skipped, and night sweats is the transition; and a mixed set, which is common, means the order of treatment matters, because improving insulin sensitivity changes how the hormonal side behaves.

What a physician does with the result is read it against the history: cycles since the teens, weight over the past decade, pregnancies and whether blood sugar rose during them, family history of diabetes or early menopause, sleep, and what has already been tried. The question that decides the plan is what would change: if the insulin side leads, the first moves are food, resistance training and sleep, sometimes with a continuous glucose sensor to watch the response, and the cycle often steadies as a result; if the transition leads, the conversation turns to symptom relief and, where appropriate, hormone therapy; if both, the sequencing is the work. Either way the physician takes responsibility for the whole picture and coordinates with a gynecologist when one is already involved.

The deeper picture

Perimenopause is one of the most under-treated transitions in women's medicine. Many women spend years being told their labs are normal while symptoms compound, accumulating damage to sleep, mood, body composition, cognition, and bone in ways that affect decades of subsequent life. A comprehensive evaluation that includes the labs that are actually informative in this window plus careful symptom assessment usually reveals what's happening and what to do about it. Dr. Paul has substantial experience with this transition.